| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.HEALTHPOL.2005.08.006 |
| P698 | PubMed publication ID | 16214257 |
| P2093 | author name string | Meghan McMahon | |
| Steve Morgan | |||
| Craig Mitton | |||
| P433 | issue | 3 | |
| P921 | main subject | Canada | Q16 |
| P304 | page(s) | 339-351 | |
| P577 | publication date | 2005-10-06 | |
| P1433 | published in | Health Policy | Q15758180 |
| P1476 | title | The Common Drug Review: a NICE start for Canada? | |
| P478 | volume | 77 |
| Q38043434 | 'Innovation' in health care coverage decisions: all talk and no substance? |
| Q34469352 | A comparison of drug coverage in alberta before and after the introduction of the national common drug review process. |
| Q34598634 | Adherence to prescribing recommendations made on a provincial formulary |
| Q35576993 | Analysis of drug coverage before and after the implementation of Canada's Common Drug Review. |
| Q37113030 | Assurance-médicaments nationale: Le moment d'aller de l'avant |
| Q37238289 | Breadth, Depth and Agreement among Provincial Formularies in Canada. |
| Q46230521 | COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008. |
| Q41585720 | Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. |
| Q28308288 | Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer |
| Q37979271 | Common Drug Review recommendations: an evidence base for expectations? |
| Q46825568 | Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter? |
| Q33701810 | Cost shifting and timeliness of drug formulary decisions in atlantic Canada. |
| Q34362510 | Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes |
| Q48289414 | Economic evaluation of floseal compared to nasal packing for the management of anterior epistaxis. |
| Q37521051 | Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study. |
| Q34462245 | Impact of drug policy on regional trends in ezetimibe use |
| Q51952330 | Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden. |
| Q37103172 | Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand |
| Q34567661 | Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces |
| Q36876028 | Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand |
| Q51200231 | Link between process and appraisal in coverage decisions: an analysis with structural equation modeling. |
| Q37123317 | Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage |
| Q37112999 | National pharmacare: Time to move forward |
| Q33933850 | Oncology drug health technology assessment recommendations: Canadian versus UK experiences |
| Q59133098 | Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare |
| Q39781561 | Public and decision maker stated preferences for pharmaceutical subsidy decisions: a pilot study |
| Q84628674 | Re: "cost shifting and timeliness of drug formulary recommendations in atlantic canada," healthcare policy, vol. 5, no. 3, 2010 |
| Q57794313 | Role of economic evidence in coverage decision-making in South Korea |
| Q36887224 | The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care |
| Q28069734 | Universal prescription drug coverage in Canada: Long-promised yet undelivered |
| Q38902166 | Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries |
Search more.